- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02430779
Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral Neoplasms (IRE)
September 1, 2021 updated by: Fuda Cancer Hospital, Guangzhou
Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral Neoplasms: Phase I and Phase II Clinical Trial
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Renal Pelvic and Ureteral Neoplasms.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
By enrolling patients with unresectable Renal Pelvic and Ureteral Neoplasms adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous IRE for unresectable Renal Pelvic and Ureteral Neoplasms.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Biological treatment center in Fuda cancer hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Renal Pelvic and Ureteral Neoplasms diagnosed by positive biopsy or non-invasive criteria,
- Not suitable for surgical resection,
- Eastern Cooperative Oncology Group (ECOG) score of 0-1,
- A prothrombin time ratio > 50%,
- Platelet count > 80x10^9/L,
- Ability of patient to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post NanoKnife procedure,
- Able to comprehend and willing to sign the written informed consent form (ICF),
- Have a life expectancy of at least 3 months.
Exclusion Criteria:
- Cardiac insufficiency, ongoing coronary artery disease or arrhythmia,
- Any active implanted device (eg Pacemaker),
- Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception,
- Have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnife™ LEDC System,
- Are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IRE Group
irreversible electroporation for Unresectable Renal Pelvic and Ureteral Neoplasms
|
Irreversible Electroportion For Unresectable Renal Pelvic and Ureteral Neoplasms guide with ultrasound or/and CT.
Other Names:
|
No Intervention: Control
The patients without treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with Adverse events
Time Frame: 6 month
|
6 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of lesions that show no sign of recurrence 12 months after IRE
Time Frame: 12 months
|
12 months
|
|
Voltage (A minimum and maximum range of voltage for safe and effective IRE)
Time Frame: 3 months
|
A minimum and maximum range of voltage for safe and effective IRE will be
|
3 months
|
Progress free disease (PFS)
Time Frame: 12 months
|
12 months
|
|
Overall survival (OS)
Time Frame: 36 months
|
Patients will be followed for 36 months after IRE for OS analyzed.
|
36 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2015
Primary Completion (Actual)
December 1, 2020
Study Completion (Actual)
January 1, 2021
Study Registration Dates
First Submitted
April 26, 2015
First Submitted That Met QC Criteria
April 26, 2015
First Posted (Estimate)
April 30, 2015
Study Record Updates
Last Update Posted (Actual)
September 5, 2021
Last Update Submitted That Met QC Criteria
September 1, 2021
Last Verified
June 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- pelvis ureter Neoplasms-IRE-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Pelvic and Ureteral Neoplasms
-
Memorial Sloan Kettering Cancer CenterNovartis PharmaceuticalsCompletedBladder Cancer | Ureter Cancer | Renal Pelvis CancerUnited States
-
Dr Anders UllénCompletedBladder Cancer | Urothelial Carcinoma | Urethra Cancer | Ureter Cancer | Renal Pelvis CancerDenmark, Sweden
-
Dr Anders UllénBayer; Pierre Fabre Laboratories; Nordic Urothelial Cancer Oncology GroupCompletedBladder Cancer | Urothelial Carcinoma | Urethra Cancer | Ureter Cancer | Renal Pelvis CancerDenmark, Sweden
-
AstraZenecaCompletedBladder Cancer | Urethra Cancer | Ureter Cancer | Renal Pelvis Cancer | Transitional Cell Bladder CancerUnited States, Spain, United Kingdom, Germany, Canada
-
Memorial Sloan Kettering Cancer CenterFox Chase Cancer Center; University of ChicagoRecruitingBladder Cancer | Urothelial Cancer | Ureter Cancer | Renal Pelvis CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedCarcinoma, Transitional Cell | Bladder Cancer | Urethra Cancer | Ureter Cancer | Renal Pelvis CancerUnited States
-
The Affiliated Hospital of Qingdao UniversityRecruitingRenal Cell Carcinoma | Prostate Cancer | Bladder Cancer | Ureteral Calculi | Renal Calculi | Penile Cancer | Pelvic Tumor | Adrenal Tumor | Nonfunctioning Kidney | Renal Cyst | Ureteropelvic Junction Obstruction | Renal Pelvis Carcinoma | Ureteral Tumor | Duplex KidneyChina
-
Adva-TecUniversity of British ColumbiaCompletedUnilateral Ureteral Stone | Renal Stone Fragments ≤ 2mmCanada
-
Tokushukai Medical GroupUnknownRenal Insufficiency | Kidney Stone | Ureteral Stricture | Kidney Neoplasm | Ureteral TumorJapan
-
Astellas Pharma Global Development, Inc.Merck Sharp & Dohme LLC; Seagen Inc.Active, not recruitingUrologic Neoplasms | Urinary Bladder Neoplasms | Carcinoma, Transitional Cell | Ureteral Neoplasms | Urothelial Cancer | Urethral Neoplasms | Renal Pelvis NeoplasmsUnited States, Italy, Spain, Canada, France, Puerto Rico
Clinical Trials on rreversible electroporation (IRE)
-
Jewish General HospitalNot yet recruiting
-
University Hospital Inselspital, BerneTerminated
-
Amsterdam UMC, location VUmcCompletedPancreatic Cancer | Locally Advanced Pancreatic Carcinoma (LAPC) | Non-metastasized Unresectable Pancreatic CarcinomaNetherlands
-
Fuda Cancer Hospital, GuangzhouCompletedGallbladder NeoplasmsChina
-
Fuda Cancer Hospital, GuangzhouCompleted
-
Fuda Cancer Hospital, GuangzhouCompletedEsophageal NeoplasmsChina
-
National Taiwan University HospitalCompleted
-
Fuda Cancer Hospital, GuangzhouCompletedHilus Pulmonary NeoplasmsChina
-
Fuda Cancer Hospital, GuangzhouCompletedUterine Cervical NeoplasmsChina
-
Fuda Cancer Hospital, GuangzhouCompletedLung Neoplasms Accompanied by Respiratory Function InsufficiencyChina